Skip to main content
Premium Trial:

Request an Annual Quote

Craig Mello

Premium

Invitrogen said this week that RNAi pioneer Craig Mello has joined the company as a scientific advisor in the area of RNAi research.

According to Invitrogen, Mello will assist in the development and implementation of RNAi strategies at the company.

Mello is currently a professor at the University of Massachusetts medical school and a Howard Hughes investigator. Mello holds a PhD from Harvard University and a bachelor’s degree in biochemistry from Brown University. He also recently joined the scientific advisory board of RNAi therapeutics developer CytRx.

“Our association with Dr. Mello opens doors to exciting new areas of discovery in RNAi,” Claude Benchimol, Invitrogen’s senior vice president of research and development, said in a statement. “By bringing his invaluable knowledge and experience in this area to our team, we hope to outpace the growing demand for cutting-edge methods to speed drug discovery research. We are honored to have him help with our development efforts.”

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.